Nouvelles Eulerpool Cyteir Therapeutics

Eulerpool-AFX Cyteir Therapeutics

Cyteir Therapeutics Actualités des actions

Cyteir Therapeutics est surveillé par de nombreux journalistes et investisseurs du monde entier. Nous regroupons ici les dernières actualités Cyteir Therapeutics.

• 7 mars ·

  Yahoo
  Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq
• 7 mars ·

  Thefly.com
  Cyteir Therapeutics announces timeline for voluntarily delisting from Nasdaq
• 20 février ·

  Business Wire
  Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
• 5 janvier ·

  Thefly.com
  Cyteir Therapeutics downgraded to Underperform at BofA, coverage terminated
• 1 novembre ·

  Fintel
  Cyteir Therapeutics (CYT) Price Target Increased by 20.00% to 3.06
• 12 octobre ·

  Yahoo
  Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile
• 12 octobre ·

  Thefly.com
  Cyteir: Cohort of CYT-0851 in combo for ovarian cancer well tolerated
• 18 septembre ·

  SeekingAlpha
  Cyteir: Although The Company Is Winding Down, The Lead Asset Had Promise
• 11 juillet ·

  Fintel
  Fmr Now Owns 2.33% of Cyteir Therapeutics (CYT)
• 6 juillet ·

  Fintel
  Cyteir Therapeutics (CYT) Price Target Increased by 7.14% to 2.55